21:15 , Aug 7, 2019 |  BC Extra  |  Clinical News

Rhythm data sets up submissions for ultra-rare obesity disorders

Two new Phase III readouts pave the way for Rhythm Pharmaceuticals to make its first regulatory submissions for setmelanotide to treat rare genetic disorders that result in obesity. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Wednesday that...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:01 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Rhythm raises $151.4M in follow-on

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) raised $151.4 million on June 20 through the sale of 5.7 million shares at $26.42 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Needham. The price is...
14:14 , Jun 21, 2018 |  BC Extra  |  Financial News

Rhythm raises $151.4M in follow-on

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) raised $151.4 million through the sale of 5.7 million shares at $26.42 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Needham. The price is an 8% discount...
05:06 , Mar 20, 2018 |  BC Extra  |  Preclinical News

Rhythm estimates mutations in genes tied to obesity

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) presented an analysis of genetic epidemiology data at the Endocrine Society meeting in Chicago suggesting that about 12,800 Americans are homozygous or compound heterozygous for known and predicted loss-of-function variants in...
18:58 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Rhythm reports Phase II data of setmelanotide to treat Bardet-Biedl Syndrome

In October, Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) reported preliminary data from 5 Bardet-Biedl Syndrome patients with morbid obesity and hyperphagia in the Phase II portion of a Phase II/III trial showing that setmelanotide (RM-493) reduced body...
16:55 , Oct 6, 2017 |  BC Week In Review  |  Financial News

Rhythm rises on $119.9M IPO

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) gained 76% in its first day of trading on Oct. 5 after raising $119.9 million through the sale of 7.1 million shares at $17 in a bumped-up IPO underwritten by Morgan...
20:31 , Oct 5, 2017 |  BC Extra  |  Financial News

Rhythm rises on $119.9M IPO

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) gained $13 (76%) to $30 in its first day of trading Thursday after raising $119.9 million through the sale of 7.1 million shares at $17 in a bumped-up IPO underwritten by...
19:21 , Jul 13, 2017 |  BC Innovations  |  Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...